Search bioRxiv⌕ Search

Biology subjects

Lobastova, L.

Publications and source records attributed to Lobastova, L..

2 recordsLinked to original sources

Tumour-derived factors prime microglia for immune checkpoint-mediated T-cell regulation

Tumour-associated microglia are major regulators of the immune microenvironment in brain malignancies, yet the early mechanisms by which tumour-derived signals shape their immune phenotype remain poorly understood. We used quantitative proteomic analysis on microglia upon tumour exposure and observed extensive remodelling of the microglial proteome following exposure to tumour-conditioned media, indicating that soluble mediators represent the dominant drivers of early microglial activation. Microglia reprogramming was characterized by coordinated upregulation of inflammatory mediators together with proteins involved in antigen presentation and T-cell regulation, including MHC-I, PD-L1 and Galectin-9. Flow cytometric validation using multiple murine and human cell models confirmed the increased expression of PD-L1 and MHC-I on microglia following exposure to tumour-derived conditioned media. Subsequently, tumour-conditioned microglia promoted expression of the inhibitory receptors PD-1 and TIM-3 on T-cells after coculture. Importantly, integration of publicly available single-cell RNA sequencing datasets and cell-cell communication analysis further demonstrated that this immune-regulatory program is recapitulated in microglia from patients with brain tumours. Together, our findings identify an early, soluble factor-driven microglial activation program that precedes direct tumour contact and integrates inflammatory activation with immune checkpoint regulation. These results provide a mechanistic framework for the early establishment of an immunosuppressive brain tumour microenvironment and highlight microglial immune checkpoint pathways as potential targets for therapeutic intervention.

cancer biology↗

Loss of TP53 mediates suppression of Macrophage Effector Function via Extracellular Vesicles and PDL1 towards Resistance against Chemoimmunotherapy in B-cell malignancies

Chemoimmunotherapy (CIT) is the standard of care in B-cell malignancies. It is relying on synergistic effects of alkylating chemotherapy and monoclonal antibodies via secretory crosstalk with effector macrophages. Here, we observed that loss of p53 function mediates resistance to CIT by suppressing macrophage phagocytic function. Loss of p53 leads to an upregulation of PDL1 and an increased formation of extracellular vesicles (EVs). EVs directly inhibit macrophage phagocytosis by PDL1 surface expression. Suppression of phagocytic function by lymphoma cell-derived EVs could be abrogated by pre-incubation of EVs with anti-PDL1 antibodies, CRISPR-KO of PDL1 and abrogation of EV formation by RAB27A-KO in lymphoma cells. Immune checkpoint inhibition represents a viable strategy to overcome EV-mediated resistance to chemoimmunotherapy in lymphoma. SignificanceLoss of TP53 mediates cell autonomous resistance to genotoxic chemotherapy, moreover non-cell autonomous effects may cause therapy resistance mediated by the tumor microenvironment. We identify a TP53-dependent mechanism that mediates resistance to synergistic chemoimmunotherapy by increasing formation of EVs and expression of the PDL1 immune checkpoint. PDL1 on EVs is directly responsible for macrophage suppression, preventing the exertion of the essential effector function of antibody-dependent cellular phagocytosis. This novel mechanism of resistance is in turn targetable by PDL1 checkpoint inhibition. Enhanced EV-release and immune checkpoint expression in lymphoma are novel mechanisms of macrophage modulation in the lymphoma microenvironment. We provide a novel principle of resistance to chemoimmunotherapy (CIT) representing of immediate relevance to treatment of refractory B-cell lymphoma. HighlightsO_LILoss of TP53 in B-cell lymphoma induces resistance towards chemoimmunotherapy (CIT) by inhibition of macrophage effector function through PDL1 upregulation C_LIO_LILoss of TP53 increases formation of extracellular vesicles (EVs) carrying PDL1 C_LIO_LIEVs inhibit antibody-mediated cellular phagocytosis (ADCP), a key macrophage effector function in CIT C_LIO_LITargeting PDL1 on EVs with immune checkpoint inhibitors overcomes TP53-mediated resistance to CIT C_LI

cell biology↗